logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 20 of 36 Items
Showing 1 - 20 of 36 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (20)
  • CSV
  • BibTeX
  • EndNote
  • All Results (36)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter

Advanced HIV disease at antiretroviral therapy (ART) initiation despite implementation of expanded ART eligibility guidelines during 2007-2012 in Khayelitsha, South Africa

Patten GE, Cox V, Stinson K, Boulle AM, Wilkinson LS
2014-04-23 • Clinical Infectious Diseases
2014-04-23 • Clinical Infectious Diseases
Journal Article
|
Review

Cohort profile: the Khayelitsha antiretroviral programme, Cape Town, South Africa

Stinson K, Goemaere E, Coetzee D, van Cutsem G, Hilderbrand K,  et al.
2016-05-20 • International Journal of Epidemiology
Journal Article
|
Research
Journal Article
|
Short Report

HIV testing and antiretroviral therapy initiation at birth: Views from a primary care setting in Khayelitsha

Nelson AM, Maritz J, Giddy J, Frigati L, Rabie H,  et al.
Journal Article
|
Letter

Linezolid in drug-resistant tuberculosis: haste makes waste

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V,  et al.
2015-12-01 • European Respiratory Journal
2015-12-01 • European Respiratory Journal
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Pre-Print
Journal Article
|
Letter
Journal Article
|
Research

Growth and mortality outcomes for different antiretroviral therapy initiation criteria in children aged 1-5 years: a causal modelling analysis

Journal Article
|
Commentary

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...
2016-05-20 • International Journal of Epidemiology

Diagnostic accuracy of tuberculin skin test self-reading by HIV patients in a low-resource setting

Cox V, De Azevedo V, Stinson K, Wilkinson LS, Rangaka MX,  et al.
2015-11-01 • International Journal of Tuberculosis and Lung Disease
2015-11-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The World Health Organization recommends tuberculin skin tests (TSTs) where feasible to identify individuals most likely to benefit from isoniazid preventive therapy (IPT)...
2015-04-28 • Southern African Journal of HIV medicine
2015-04-28 • Southern African Journal of HIV medicine

Outcomes of patients enrolled in an antiretroviral adherence club with recent viral suppression after experiencing elevated viral loads

Sharp J, Wilkinson LS, Cox V, Cragg C, van Custem G,  et al.
2019-06-11 • Southern African Journal of HIV medicine
2019-06-11 • Southern African Journal of HIV medicine
BACKGROUND
Eligibility for differentiated antiretroviral therapy (ART) delivery models has to date been limited to low-risk stable patients.
OBJECTIVES
We examined the outcom...

Time to ART initiation among patients treated for rifampin-resistant tuberculosis in Khayelitsha, South Africa: Impact on mortality and treatment success

Daniels J, Khogali MA, Mohr E, Cox V, Moyo S,  et al.
2015-11-10 • PLOS One
2015-11-10 • PLOS One
SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.

OBJECTIVE
To describe time to antiretroviral trea...

Patients lost to care are more likely to be viremic than patients still in care

Stinson K, Ford NP, Cox V, Boulle AM
2014-02-05 • Clinical Infectious Diseases
2014-02-05 • Clinical Infectious Diseases

Errors generated by a point-of-care CD4+ T-lymphocyte analyser: a retrospective observational study in nine countries

Fajardo E, Metcalf CJ, Piriou E, Gueguen M, Maman D,  et al.
2015-06-25 • Bulletin of the World Health Organization
2015-06-25 • Bulletin of the World Health Organization
OBJECTIVE
To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associ...

The need to accelerate access to new drugs for multidrug-resistant tuberculosis

Cox HS, Furin J, Mitnick CD, Daniels C, Cox V,  et al.
2015-07-01 • Bulletin of the World Health Organization
2015-07-01 • Bulletin of the World Health Organization
Approximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10...

Optimal Timing of Antiretroviral Treatment Initiation in HIV-Positive Children and Adolescents: a Multiregional Analysis from Southern Africa, West Africa and Europe

Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L,  et al.
2016-06-24 • International Journal of Epidemiology
2016-06-24 • International Journal of Epidemiology
Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents. Methods: A total of 20 576 antiretroviral treatm...

An analysis of the HIV testing cascade of a group of HIV-exposed infants from birth to 18 months in peri-urban Khayelitsha, South Africa

Nelson AM, Cassidy T, Duran LT, Cox V, Wedderburn C,  et al.
2022-01-14 • PLOS One
2022-01-14 • PLOS One
BACKGROUND
Despite the reduction of HIV mother-to-child transmission, there are concerns regarding transmission rate in the breastfeeding period. We describe the routine uptake of 6 ...

MSF Access Campaign drug-resistant tuberculosis research and development case study May 2020

Cox V, Perrin C, Athersuch K, Martin M M, Alsalhani A
2020-06-01 • OSF Preprints
2020-06-01 • OSF Preprints
Two novel drugs, bedaquiline and delamanid, have recently become available to treat drug resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB trea...

Better treatment of XDR tuberculosis needed in South Africa

Cox HS, van Cutsem G, Cox V
2014-08-01 • Lancet
2014-08-01 • Lancet
Schomaker M, Davies A, Malateste K, Renner L, Sawry S,  et al.
2015-10-16 • Epidemiology
2015-10-16 • Epidemiology

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...